GHRP-2 (5 mg Vial) Dosage Protocol

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (GHRP-2, 5 mg each):
  • 8 weeks: approximately 2 vials required
  • 12 weeks: approximately 4 vials required
  • 16 weeks: approximately 5 vials required
• Insulin Syringes (U-100):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (2 vials): 6 mL — 1 bottle required (10 mL each)
  • 12 weeks (4 vials): 12 mL — 2 bottles required (10 mL each)
  • 16 weeks (5 vials): 15 mL — 2 bottles required (10 mL each)
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs — 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs — 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs — 3 boxes required (100 swabs each)

GHRP-2 5 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

• Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
• Typical daily range: 100–300 mcg once daily subcutaneously.
• Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F).

GHRP-2 (Growth Hormone-Releasing Peptide-2) is a synthetic hexapeptide that stimulates potent, dose-dependent growth hormone release by activating ghrelin receptors^[1]. Clinical studies predominantly employ once-daily subcutaneous administration to elicit robust pulsatile GH release while minimizing receptor desensitization^[2][3]. This educational protocol presents a practical gradual titration approach with clear insulin-syringe measurements.

Concise summary of the once-daily regimen.

• Goal: Stimulate endogenous growth hormone secretion through ghrelin receptor activation^[1].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 100–300 mcg daily with gradual titration; higher doses show dose-dependent responses but may offer limited added benefit with routine use^[4].
• Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated with use-by determined by the exact product instructions.

Suggested daily titration approach.

• Start: 100 mcg daily (Weeks 1–2); this starting dose provides strong GH pulse while allowing tolerance assessment.
• Mid-level: 150 mcg daily (Weeks 3–4) to enhance GH response if well tolerated.
• Target: 200 mcg daily (Weeks 5–16) for maximal effect in most research scenarios; advanced researchers may optionally increase to 250–300 mcg.
• Frequency: Once per day (subcutaneous); evening administration may align with nocturnal GH rhythms.
• Cycle Length: 8–16 weeks; some attenuation may occur in first 1–2 weeks but response stabilizes with continued dosing^[3].

Proper storage preserves peptide potency.

• Lyophilized: Follow the exact product’s storage temperature and expiration instructions; keep the vial dry and protected from light.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow formulation-specific use-by and sterile-handling instructions. Do not assume aliquoting or freezing extends stability; avoid repeated freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Always protect from light and heat.

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipodystrophy^[13].
• Very frequent dosing (e.g., every 2 hours) can cause progressive attenuation due to acute tachyphylaxis^[3]; once-daily administration avoids this issue.
• Multiple daily injections (2–3×) have been explored but require strict adherence and may offer limited added benefit^[5][6].
• Document daily dose and site rotation to maintain consistency.

GHRP-2 is a synthetic growth hormone secretagogue that binds to and activates ghrelin (GH secretagogue) receptors^[1]. This activation triggers potent, pulsatile release of growth hormone from the pituitary gland in a dose-dependent manner^[4]. Clinical studies in GH-deficient children demonstrated meaningful GH increases even at low doses (0.3–3.0 mcg/kg), with escalating doses over several months showing sustained efficacy^[2]. In healthy adults, doses of 100 mcg SC daily produce acute GH stimulation^[3], while routine protocols typically maintain 100–300 mcg/day to balance efficacy with receptor sensitivity. The peptide has been well tolerated in clinical trials with no significant adverse effects or toxicity reported at these dosage ranges^[2].

Observations from clinical and preclinical literature.

• Stimulates robust pulsatile GH release that may support favorable body composition changes and metabolic effects^[1][2].
• In combination therapies (e.g., with GHRH analogs), can significantly increase IGF-1 levels when administered with perfect compliance^[5][6].
• Generally well tolerated with placebo-like safety profile; transient side effects may include mild hunger sensation or flushing.
• Long-term therapy (8–24 months in GH-deficient subjects) has maintained positive effects on growth velocity with careful monitoring^[2].
• Occasional mild injection-site reactions (redness, irritation) may occur with subcutaneous administration.

Complementary strategies for optimal outcomes.

• Maintain adequate protein intake and balanced nutrition to support the anabolic effects of elevated GH.
• Combine with resistance training to maximize body composition benefits.
• Prioritize sleep quality, as GH pulses naturally occur during deep sleep; evening administration may complement this rhythm.
• Manage stress effectively to support consistent adherence and recovery.
• Stay well hydrated to support metabolic processes.

General subcutaneous guidance from clinical best-practice resources^[11].

• Clean the vial rubber stopper and skin with alcohol swabs; allow to dry completely.
• Use a fine insulin syringe (typically 29–31 gauge, 0.5-inch needle).
• Pinch an inch of skin fat (abdomen, thigh, or outer upper arm); insert needle at 45° to 90° into subcutaneous tissue^[11]. (Use 90° angle if ample fatty tissue; 45° for leaner individuals to avoid intramuscular injection.)
• Do not aspirate for subcutaneous injections—aspiration is unnecessary and can cause needless tissue trauma^[11].
• Inject slowly and steadily; wait a few seconds before withdrawing needle at same angle.
• Apply gentle pressure with swab if needed; do not massage or rub injection site.
• Rotate sites systematically to prevent irritation and lipodystrophy—space injections at least 1 inch apart^[13].

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

• 1
  
  Domest Anim Endocrinol
  — Effects of GHRP-2 on GH release and growth performance in swine (mechanism and receptor activation)

  View Source
• 2
  
  J Clin Endocrinol Metab
  — Effects of eight months treatment with graded doses of GHRP-2 in GH-deficient children

  View Source
• 3
  
  Eur J Endocrinol
  — Five-day treatment with daily subcutaneous GHRP-2: response attenuation and IGF-I effects in healthy young men

  View Source
• 4
  
  Endocrine
  — GH/IGF-1 response to acute and chronic GHRP-2, GHRH 1-44, and their combination in older adults

  View Source
• 5
  
  Am J Men’s Health
  — Growth hormone secretagogue treatment in hypogonadal men raises serum IGF-1 levels

  View Source
• 6
  
  Sex Med Rev (PMC)
  — The safety and efficacy of growth hormone secretagogues: comprehensive review

  View Source
• 11
  
  Medicine LibreTexts (BCcampus)
  — Intradermal and subcutaneous injections: clinical procedures for safer patient care

  View Source
• 13
  
  Medicine LibreTexts (BCcampus)
  — Site rotation and lipodystrophy prevention in subcutaneous injections

  View Source
• 14
  
  Pure Lab Peptides
  — GHRP-2 (5 mg) product page (quality documentation and batch COAs)

  View Source
• 10
  
  Nurseslabs
  — Subcutaneous administration technique: comprehensive nursing guide

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.